194 related articles for article (PubMed ID: 34203465)
1. Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.
Chen MY; Yadav VK; Chu YC; Ong JR; Huang TY; Lee KF; Lee KH; Yeh CT; Lee WH
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34203465
[TBL] [Abstract][Full Text] [Related]
2. Correction: Chen et al. Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis.
Chen MY; Yadav VK; Chu YC; Ong JR; Huang TY; Lee KF; Lee KH; Yeh CT; Lee WH
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831696
[No Abstract] [Full Text] [Related]
3. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
[TBL] [Abstract][Full Text] [Related]
7. HANR Enhances Autophagy-Associated Sorafenib Resistance Through miR-29b/ATG9A Axis in Hepatocellular Carcinoma.
Shi Y; Yang X; Xue X; Sun D; Cai P; Song Q; Zhang B; Qin L
Onco Targets Ther; 2020; 13():2127-2137. PubMed ID: 32210579
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
9. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ
Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396
[TBL] [Abstract][Full Text] [Related]
10. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
12. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
13. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
Zhou B; Lu Q; Liu J; Fan L; Wang Y; Wei W; Wang H; Sun G
Int J Biol Sci; 2019; 15(9):1905-1920. PubMed ID: 31523192
[TBL] [Abstract][Full Text] [Related]
14. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
15. Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells.
Wang W; Ding B; Lou W; Lin S
Front Cell Dev Biol; 2020; 8():724. PubMed ID: 32903337
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma.
Gu D; Tong M; Wang J; Zhang B; Liu J; Song G; Zhu B
Discov Oncol; 2023 May; 14(1):66. PubMed ID: 37171645
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA SNHG16 induces sorafenib resistance in hepatocellular carcinoma cells through sponging miR-140-5p.
Ye J; Zhang R; Du X; Chai W; Zhou Q
Onco Targets Ther; 2019; 12():415-422. PubMed ID: 30655679
[TBL] [Abstract][Full Text] [Related]
18. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
19. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
20. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
